PCSK9 polymorphism in a Tunisian cohort: Identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk

Molecular and Cellular Probes

Volumn 29, Issue 1, 2015, Pages 1-6

  Slimani, Afef ^a   Hrira, Mohamed Yahia ^b   Najah, Mohamed ^a   Jomaa, Walid ^c   Maatouk, Faouzi ^c   Hamda, Khaldoun Ben ^c   Abifadel, Marianne ^d,e   Rabès, Jean Pierre ^e,f   Boileau, Catherine ^e,g   Rouis, Mustapha ^h   Slimane, Mohamed Naceur ^a   Varret, Mathilde ^e  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^d SAINT JOSEPH UNIVERSITY   (Lebanon)

^e University Paris VII   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g BICHAT HOSPITAL   (France)

^h Un iversité Pierre et Marie Curie   (France)

Author keywords

C.61_63dupCTG; Coronary artery disease; PCSK9 gene; Rs72555377

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DISEASE SEVERITY; DNA POLYMORPHISM; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; STABLE ANGINA PECTORIS; TUNISIAN; CASE CONTROL STUDY; CAUCASIAN; CORONARY ARTERY DISEASE; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

AGED; ALLELES; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASES; REGRESSION ANALYSIS; SEQUENCE DELETION; SERINE ENDOPEPTIDASES; TUNISIA;

EID: 84923576879     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2014.09.001     Document Type: Article

References (37)

1. Papafaklis M.I., Koskinas K.C., Chatzizisis Y.S., Stone P.H., Feldman C.L. In-vivo assessment of the natural history of coronary atherosclerosis: vascular remodeling and endothelial shear stress determine the complexity of atherosclerotic disease progression. Curr Opin Cardiol 2010, 25:627-638.
2. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
3. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. JBiol Chem 2004, 279:48865-48875.
4. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. JBiol Chem 2007, 282:18602-18612.
5. Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. JBiol Chem 2008, 283:2363-2372.
6. Sun H., Samarghandi A., Zhang N., Yao Z., Xiong M., Teng B.B. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 2012, 32:1585-1595.
7. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
8. Abifadel M., Rabès J.P., Devillers M., Munnich A., Erlich D., Junien C., et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009, 30:520-529.
9. Davignon J., Dubuc G., Seidah N.G. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 2010, 12:308-315.
10. Yue P., Averna M., Lin X., Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a caucasian population. Hum Mutat 2006, 27:460-466.
11. Abifadel M., Rabès J.P., Jambart S., Halaby G., Gannagé-Yared M.H., Sarkis A., et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat 2009, 30:E682-E691.
12. Abifadel M., Bernier L., Dubuc G., Nuel G., Rabès J.P., Bonneau J., et al. APCSK9 variant and familial combined hyperlipidaemia. JMed Genet 2008, 45:780-786.
13. Pisciotta L., Sallo R., Rabacchi C., Wunsch A., Calandra S., Bertolini S. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolemia. Nutr Metab Cardiovasc Dis 2012, 22:831-835.
14. Chen S.N., Ballantyne C.M., Gotto A.M., Tan Y., Willerson J.T., Marian A.J. Acommon PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. JAm Coll Cardiol 2005, 45:1611-1619.
15. Wang J.G., Staessen J.A., Franklin S.S., Fagard R., Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005, 45:907-913.
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26:S5-S20.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 6:499-502.
18. Miller S.A., Dykes D.D., Polesky H.F. Asimple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III) final report. Circulation 2002, 106:3143-3421.
20. Abdel-Maksoud M.F., Eckel R.H., Hamman R.F., Hokinson J.E. Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men. JClin Lipidol 2012, 6:374-381.
21. Zhang B., Menzin J., Friedman M., Korn J., Russel B. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. Curr Med Res Opin 2008, 24:2711-2717.
22. Gotto A.M., Moon J.E. Management of cardiovascular risk. The Importance of Meeting lipid Targets. Am J Cardiol 2012, 110(Suppl.1):3A-14A.
23. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
24. Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009, 5:150-159.
25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
26. Van den Hoogen P.C., Feskens E.J., Nagelkerke N.J., Menotti A., Nissinen A., Kromhout D. the relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. NEngl J Med 2000, 342:1-8.
27. Hirooka N., Kadowaki T., Sekikawa A., Ueshima H., Choo J., Miura K., et al. Influence of cigarette smoking on coronary artery and aortic calcium among random samples from populations of middle-aged Japanese and Korean men. JEpidemiol Community Health 2013, 67:119-124.
28. Aballay L.R., Eynard A.R., Díaz Mdel P., Navarro A., Muñoz S.E. Overweight and obesity: their relationship to metabolic syndrome, cardiovascular disease, and cancer in South America. Nutr Rev 2013, 71:168-179.
29. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybjaerg-Hansen A. PCSK9 R46L, lowdensity lipoprotein cholesterol levelsand risk of ischemic heart disease: 3 independent studiesand meta-analyses. JAm Coll Cardiol 2010, 55:2833-2842.
30. Guella I., Asselta R., Ardissino D., Merlini P.A., Peyvandi F., Kathiresan S., et al. Effect of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. JLipid Res 2010, 51:3342-3349.
31. Chernogubova E., Strawbridge R., Mahdessian H., Mälarstig A., Krapivner S., Gigante B., et al. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler Thromb Vasc Biol 2012, 32:1526-1534.
32. Norata G.D., Garlaschelli K., Grigore L., Raselli S., Tramontana S., Meneghetti F., et al. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis 2010, 208:177-182.
33. Aung L.H., Yin R.X., Miao L., Hu X.J., Yan T.T., Cao X.L., et al. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011, 10:5.
34. Slimane M.N., Pousse H., Maatoug F., Hammami M., Ben Farhat M. Phenotypic expression of familial hypercholesterolemia in central and southern Tunisia. Atherosclerosis 1993, 104:153-158.
35. Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012, 220:381-386.
36. Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., et al. Gene inactivation of proprotein convertase Subtilisin/Kexin type 9 reduces atherosclerosis in mice. Circulation 2012, 125:894-901.
37. Li S., Guo Y.L., Xu R.X., Zhang Y., Zhu C.G., Sun J., et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 2014, 234:441-445.